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Abstract
Background: I/D polymorphisms of ACE are associated with the plasma ACE concentration. The ACE is
associated with the angiogenesis of ovarian endothelium in vitro as well as steroidogenesis and follicular
growth in cattle. Since ACE induces a high blood supply and hypersteroidogenesis in the ovary, it may be
associated with polycystic ovary syndrome (PCOS) which exhibits hyperplasia, hypervascularity of the
ovarian theca interna and stroma, as well as disorderd steroidogenesis. Therefore, we hypothesized that
the ACE plays some roles in the human ovary. To investigate whether the ACE I/D polymorphisms are
associated with the steroidogenesis disorder in PCOS and contribute to the susceptibility of PCOS in
Chinese women, we designed a case-controlled association study in 582 individuals.
Methods: The ACE I/D polymorphisms were assessed in 582 reproductive-age women. Genotyping and
frequency of ACE I/D polymorphisms were obtained by PCR amplification that was performed on genomic
DNA isolated from blood leucocytes. Results were analyzed in respect to clinical test results.
Results: The frequencies of the D allele and the genotypic distributions (DD, ID and II) in the women
with PCOS did not differ from those in controls (P = 0.458). However, there were significant differences
in the concentrations of testosterone among three genotypes both in the PCOS patients and controls (P
= 0.0045, P = 0.0052, respectively). Differences were also found between these groups with distinct
genotypes: DD versus II and DI versus II in the PCOS patients as well as DD versus DI and DD versus II
in the controls. There were significant differences in the ratio of LH/FSH among three genotypes in the
patients (P = 0.01). However, there were no statistical differences in the BMI, AAM, E2 concentrations and
other serum hormone concentrations among the three genotypes both in the PCOS patients and controls.
Conclusion: The ACE I/D polymorphisms were not associated with the pathogenesis of PCOS. However,
the polymorphisms were associated with the steroidogenesis in the ovary. The observation indicated that
the ACE I/D polymorphisms were not the key etiological factor, which in stead may be associated with the
aggravated clinical manifestations of PCOS.
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Background
There is evidence to indicate that the RAS may influence
oocyte maturation, ovulation and steroidogenesis as well
as formation of corpus luteum through complex interac-
tions with other systems [1]. ACE, encoded by the ACE
gene, is one of the components of RAS and can be
expressed in multiple tissues including ovaries [2]. In
addition to the important role in regulating blood pres-
sure, the ACE and its products are associated with the ang-
iogenesis of ovarian endothelium in vitro [3] and the
resumption of meiosis [4,5], steroidogenesis [6], and fol-
licular growth [7] in cattle. However, there are few reports
on the roles of ACE in human ovaries. Rigat et al [8] dem-
onstrated that the inter-individual variability of the
plasma ACE concentration is associated with an insertion
(I)/deletion (D) polymorphism involving a 287-bp DNA
sequence situated in intron 16 of the ACE gene, the so-
called ACE I/D polymorphism. Thus researchers use the I/
D polymorphism as a valid marker for studying the asso-
ciations between the ACE  gene polymorphism(s) and
pathophysiological conditions.
PCOS, present in 5%–10% of reproductive-age women, is
a constellation of hyperandrogenism, hyperinsulinism
[9,10], menstrual dysfunction, and associated metabolic
and cardiovascular complications [11]. It is postulated
that the environmental and genetic factors contribute to
the etiology of PCOS [12]. During the past decades, the
roles of more than 70 candidate genes have been evalu-
ated for causal roles in PCOS; however, because of genetic
and phenotypic heterogeneity and underpowered studies,
the results of many of these studies remain inconclusive.
Patients with PCOS not only have the clinical characteris-
tics of oligomenorrhoea, hirsutism, infertility and hyper-
insulinemia but also exhibit obesity, hypertension,
dyslipidemia, and an increased pro-thrombotic state
[10,11]. They also have an increased risk of type2 diabetes
[13], impaired glucose tolerance and cardiovascular dis-
eases. Hyperplasia and hypervascularity of the ovarian
theca interna and stroma are also the prominent features
of PCOS, a leading cause of infertility [14]. As an impor-
tant regulator of blood pressure, ACE may play a potential
role in the progress of the cardiovascular diseases in the
patients with PCOS. In addition, the product of the ACE-
Angiotensin II plays a role in angiogenesis during ovula-
tion, the formation of the corpus luteum, and luteolysis in
cattle [15]. Early studies using pharmacologic approaches
indicated that receptors for angiotensin II are present on
steroidogenic cells which can synthesize steroid hor-
mones [1]. Experimental studies found that the presence
of the D allele is associated with higher levels of plasma
ACE [8]. The higher levels of plasma ACE probably leads
to a higher level of Ang-II and the disorder of the steroid
hormone synthesis. To investigate whether the ACE geno-
type is associated with the abnormal levels of hormones
in PCOS patients, we designed a case-control experiment
including 346 PCOS patients and 236 non-PCOS individ-
uals as controls.
Methods
Subjects
A total of 582 women were studied. 346 of them were
patients with PCOS and 236 were non-PCOS women as
controls. The controls were selected by excluding the diag-
nosis of PCOS according to the 2003 Rotterdam Criteria
and exhibiting normal menstrual cycles (<32 days). All
the individuals in the control group were without obesity,
hirsutism (the F-G hirsutism score ≥ 7), acne, or overmuch
sebum. All the women recruited for the study were from
the Chinese Han ethnic group. The study was approved by
Medical School of Nanjing University, and informed con-
sent was obtained from every study participant.
PCOS diagnostic criteria and hormone measurements
Patients with PCOS were diagnosed by the 2003 Rotter-
dam Criteria [16]. The Rotterdam Criteria requires at least
two of the following indicators for diagnosis of PCOS:
clinical or biochemical signs of hyperandrogenism (Table
1), oligomenorrhea or amenorrhea, and presence of poly-
cystic ovarian (PCO) morphology on ultrasound (Table
1), with the exclusion of other causes of hyperandrogen-
ism such as hyperprolactinemia, androgen-secreting
tumors, Cushing's syndrome and nonclassic congenital
Table 1: The criteria of clinical/biochemical hyperandrogenism and PCO
Clinical features Hirsutism There're pelages around anocheilon, lower mandible, areola mammae and 
the midline of inferior belly etc. Note:Although some patients have acnes, 
our gynecologists mainly rely on the hirsutism as the clinical features of 
hyperandrogenism.
Biochemical indices Total testosterone (T) in the serum (nmol/L) Normal: < 1.4; Hyperandrogenism: > 1.4
(during the third to the fifth day of the menstrual cycle)
The criteria of PCO 1. The follicular phase ovary lacking follicles larger than 10 mm in diameter
2. The presence of 12 or more follicles measuring 2–9 mm in diameter, or 
increased ovarian volume (>10 mL)BMC Medical Genetics 2009, 10:64 http://www.biomedcentral.com/1471-2350/10/64
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adrenal hyperplasia. We calculated the body mass index
(BMI = body weight in kilograms divided by square of
height in meters) to assess obesity. The peripheral blood
was obtained by a single venipuncture during the 3rd to
the 5th day of the menstrual cycle for those who had men-
struation and at any time for those who had amenorrhea.
All peripheral blood samples were obtained between 8
AM and 9 AM after a 12-hour overnight fast. None of the
study participants had been taking hormonal medica-
tions, including contraceptive pills, for the previous three
months before the hormone measurement. Blood sam-
ples were immediately centrifuged, and then serum was
separated and frozen at -80°C until assayed. Levels of
total testosterone (T), follicle-stimulating hormone
(FSH), luteinizing hormone (LH), total testosterone (T),
and estradiol (E2) in the sera were measured by RIA (Bei-
jing Northern Institute of Biological Technology of China
and the CIS Company of France). The intra- and inter-
assay coefficients of variation of all the assays were less
than 10%.
Polymorphism genotype analysis
Genomic DNA was extracted from venous blood samples
using Chelex®-100 as a medium (Promega, Madison, WI,
USA). For each subject, the presence (allele I) or absence
(allele D) of the 287-bp Alu repeat in intron 16 of the ACE
gene was determined by measuring the size of DNA frag-
ments after polymerase chain reaction (PCR) amplifica-
tion. The PCR conditions were as described by Brigitte
Rigat et al. [17], using a primer pair of 5'-CTG GAG ACC
ACT CCC ATC CTT TCT-3' (sense oligo) and 5'-GAT GTG
GCC ATC ACA TTC GTC AGA T-3' (anti-sense oligo). PCR
amplification was carried out in a total volume of 25 μL
containing 50 ng template DNA, 10 pmols of each primer,
2.5  μL STR (short tandem repeat) 10×buffer (STR
10×buffer, Promega, Madison, WI, USA) and 1.5 U of Taq
DNA polymerase (Promega, Madison, WI, USA). The PCR
was performed in a PTC-100 (MJ Research™, Incorpo-
rated) thermocycler as follows: An initial denaturation
step of 2.5 minutes at 94°C, then 30 cycles consisting of
30 seconds of denaturation at 94°C, 105 seconds of
annealing at 60°C, and 1.5 minutes of extension at 72°C.
The PCR products were separated on a 2% agarose gel,
and DNA was visualized by ethidium bromide staining
(Figure 1). The expected PCR product was a 190-bp frag-
ment in the presence of the deletion (D) allele and a 490-
bp fragment in the presence of the insertion (I) allele.
Thus, each DNA sample revealed one of three possible
patterns after electrophoresis: a 490-bp band (genotype
II), a 190-bp band (genotype DD), or both 490-and 190-
bp bands (genotype ID).
Statistical analysis
The frequencies of ACE alleles and genotypes among the
patients and controls were obtained by direct enumera-
tion based on the PCR results, and the deviation from
Hardy-Weinberg equilibrium was evaluated using the χ2-
test. Genotypic distributions between the patients and
controls were compared by χ2-test of the 2 × 3 tables. The
analysis was performed using the SAS system software
(SAS Institute Inc., Cary, USA). The results of serum hor-
mone levels were reported as MEANS ± SD. The regression
and correlation tests were used to analyze the association
of age or BMI and the concentrations of the hormone. Dif-
ferences in serum hormone levels among different geno-
typic individuals were assessed by using one way analysis
of variance (ANOVA). Tukey-test was used for further
analysis of the differences among the three genotypes,
which was performed using the SAS system software. P <
0.05 was considered statistically different.
Results
The overall characteristics of the PCOS patients and the
controls were presented in Table 2. There were no correla-
tions between the age or BMI and the concentrations of
the hormone. The frequencies of D allele were 51.45%
and 55.3% in the patients (n = 346) and the controls (n =
PCR detection of the I/D polymorphism of the ACE gene  (lanes 1–3) Figure 1
PCR detection of the I/D polymorphism of the ACE 
gene (lanes 1–3). PCR conditions were as described by 
Brigitte Rigat et al [11]. 2% agarose gel electrophoresis, 
ethidium bromide staining and UV transillumination were 
performed. Lane Marker: DNA marker. Lane 1: Band of 490 
bp indicating genotype II; Lane 2: Bands of 490 bp and 190 bp 
indicating genotype I/D; Lane 3: Band of 190 bp indicating 
genotype DD.BMC Medical Genetics 2009, 10:64 http://www.biomedcentral.com/1471-2350/10/64
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236), respectively. In all the 582 study subjects, the ACE
genotypic distributions were 28.32% (DD), 46.24% (ID),
25.43 (II) in the patients, and 32.63% (DD), 45.34%
(ID), 22.03% (II) in the controls, respectively. In both the
patient and control groups the genotypic distributions
were in agreement with Hardy-Weinberg equilibrium (χ2
= 1.914 and 1.623, respectively, P > 0.05). No significant
difference was observed in the frequency of the genotypic
distributions between the patients with PCOS and the
non-PCOS controls (P = 0.458) (Table 3).
Data analysis
By ANOVA analysis, we observed significant differences in
the concentrations of testosterone among three genotypes
in both the patients and the controls (P = 0.0045, P =
0.0052, respectively) (Table 3). Further analysis (Tukey)
showed statistical differences (P < 0.05) between these
groups with distinct genotypes: DD versus II and DI versus
II in the PCOS patients as well as DD versus DI and DD
versus II in the controls. In both patients and controls, the
concentration of testosterone in the DD genotype was
higher than that in the II genotype. Significant differences
were also found in the ratio of LH/FSH among the three
genotypes in the patients (P = 0.01). In contrast, no statis-
tical differences in the concentration of estradiol (E2)
were observed among the three genotypes in both patients
and the controls (Table 3). We found no statistical differ-
ences of the BMI, AAM and other serum hormone concen-
trations among different genotypes in patients and
controls.
Discussion
In this case-control study the D allele of the ACE gene had
no influence on the occurrence of PCOS. No significant
differences were observed in the distribution of the geno-
types between the patients and the controls. Regardless of
the criterion used for assessing patients of PCOS (oli-
gomenorrhea or amenorrhea; presence of polycystic ovar-
ian (PCO) morphology on ultrasound, and clinical or
laboratory evidence of hyperandrogenism), no differences
were observed among the three genotypes. These results
suggested that the D allele of the ACE gene was not a
major etiological factor for PCOS. Our current finding is
contrary to the observation reported by Yunxia Cao et al
[18,19] in a smaller sample, which suggests that the D
allele is associated with the enhanced RAS and the forma-
tion of polycystic ovary and hyperandrogen. Several pos-
sibilities may account for this discrepancy: first, the
Table 2: The overall characteristics of PCOS patients and controls
_ N Age (years) AAM (years) BMI (kg/m2) FSHIU/L LHIU/L LH/FSH T (nMol/L) E2 (pMol/L)
PCOS 346 26.49 ± 4.0* 14.57 ± 1.62 22.80 ± 3.79* 8.14 ± 5.91*
(N = 325)
20.39 ± 20.3*
(N = 325)
2.63 ± 1.33*
(N = 325)
4.04 ± 4.12*
(N = 325)
226.92 ± 117.04*
(N = 325)
Control 236 31.64 ± 4.35 14.75 ± 2.66 21.32 ± 2.32 6.97 ± 2.16
(N = 219)
4.55 ± 2.16
(N = 219)
0.67 ± 0.33
(N = 219)
1.6 ± 3.82
(N = 219)
171.64 ± 140.68
(N = 219)
Note: *P < 0.05 vs control. We failed to assay the hormone levels in several women with PCOS and controls.
Table 3: Anthropometric characteristics and serum hormone concentrations in women with different genotypes
ACE genetype PCOS CONTROL
DD ID II P DD ID II P
N 98 160 88 _ 77 107 52 0.458a
Frequency (%) 28.32 46.24 25.43 32.63 45.34 22.03
Age (years) 26.63 ± 3.86 26.31 ± 4.16 26.93 ± 3.69 0.75 32.62 ± 3.43 31.63 ± 4.45 31.15 ± 4.66 0.38
AAM (years) 14.43 ± 1.77 14.66 ± 1.61 14.44 ± 1.45 0.67 15.23 ± 3.73 14.59 ± 1.52 14.63 ± 2.76 0.58
BMI (kg/m2) 22.12 ± 3.23 23.15 ± 4.02 22.55 ± 3.66 0.33 20.75 ± 2.06 21.49 ± 2.46 21.48 ± 2.33 0.37
FSH (IU/L) 8.22 ± 5.00
(N = 92)
7.91 ± 4.5
(N = 151)
8.83 ± 10.25
(N = 83)
0.77 6.7 ± 2.87
(N = 72)
7.52 ± 2.3
(N = 99)
6.67 ± 1.49
(N = 48)
0.13
LH (IU/L) 20.94 ± 21.53
(N = 92)
21.98 ± 22
(N = 151)
13.96 ± 7.33
(N = 83)
0.19 4.68 ± 2.57
(N = 72)
4.77 ± 1.94
(N = 99)
4.31 ± 2.12
(N = 48)
0.55
LH/FSH 2.75 ± 1.6
(N = 92)
2.78 ± 1.26
(N = 151)
1.93 ± 0.88
(N = 83)
0.01 0.73 ± 0.34
(N = 72)
0.68 ± 0.37
(N = 99)
0.65 ± 0.3
(N = 48)
0.66
T* (nMol/L) 2.90 ± 1.11
(N = 92)
3.01 ± 1.32
(N = 151)
2.11 ± 0.9
(N = 83)
0.0045 1.62 ± 1.01
(N = 72)
1.03 ± 0.73
(N = 99)
1.11 ± 0.53
(N = 48)
0.0052
E2 (pMol/L) 259.7 ± 128.72
(N = 92)
223.49 ± 109.96
(N = 151)
190.46 ± 114.8
(N = 83)
0.053 191.52 ± 152.71
(N = 72)
189.84 ± 176.82
(N = 99)
147.35 ± 93.67
(N = 48)
0.25
Note: a:P = 0.458, genotypic distributions in women with PCOS vs those in the controls.
P* = 0.0001 (the total T values of women with PCOS vs those of controls) We failed to assay the hormone levels in several women with PCOS and 
controls.BMC Medical Genetics 2009, 10:64 http://www.biomedcentral.com/1471-2350/10/64
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sample size in Cao's study was smaller, which may limit
its representation of the colonia; second, the method cho-
sen by Cao et al and us to detect the polymorphism may
cause a misclassification of approximately 4 to 5% of the
ID heterozygotes to the DD homozygotes [20]. We tried
to correct this error. An additional PCR analysis is, there-
fore, needed for the confirmation of the DD genotypes
obtained in the first standard PCR, including a new sense
primer that is insertion-specific [20].
Although there were no significant differences in the dis-
tributions of the genotypes between the patients and the
controls, we observed significant differences in the con-
centrations of testosterone among the three genotypes
both in the patients and the controls (Table 3). By further
analysis (Tukey-test), we found that, both in the patients
and controls, the concentrations of testosterone in the DD
genotype were higher than those in the II genotype (P <
0.05 respectively). The DD genotype was associated with
a higher level of ACE than either the ID or II genotype [8],
which implicates that the increased lever of ACE may be
associated with the higher concentration of testosterone.
It also indicates that the I/D polymorphisms of the ACE
gene may directly or indirectly contribute to the expres-
sion of the testosterone in the ovaries. There can be a
number of explanations for the phenomenon: firstly, the
ACE is associated with the angiogenesis of ovarian
endothelium in vitro [3]. Although there's no report
about ACE promoting the angiogenesis of ovarian
endothelium in vivo in human, the ovary has higher
blood supply than the other organs in the body [21,22]
and the majority of steroidogenic cells are in contact with
at least one capillary [23]. If the higher level of ACE can
stimulate the angiogenesis of ovarian endothelium in vivo
and increase the blood supply, it may increase the supply
of cholesterin which is the precursor of the steroid hor-
mone. It is necessary to conduct further analysis to clarify
the point. Secondly, the product of the ACE- Ang II is
shown to inhibit LH-stimulated progesterone secretion
from primary cultures of bovine corpora lutea cells [24]
and from the midluteal phase bovine corpora lutea in an
in vitro microdialysis system [25,26]. The reduced secre-
tion of progesterone will stimulate the secretion of LH
through negative feedback, which can explain the differ-
ential LH/FSH ratios in different genotypes of the patients.
In addition, a higher level of testosterone can also increase
the transformation of estrogen, which will further modu-
late the release of LH and FSH through either positive or
negative feedback.
An interesting finding was that the total T concentrations
between the I/D and D/D genotypes in the controls were
different, whereas in the PCOS patients such concentra-
tions between the I/D and I/I genotypes were different.
One interpretation of this finding is that the I/D is a sus-
ceptible genotype in the population of hyperandrogen-
ism. In the controls, the I/D and I/I genotypes
demonstrate no differences in the concentrations of T.
However, according to the prior studies, these two geno-
types have different concentrations of ACE. Two possibil-
ities may account for this observation: 1) the
concentration of T is not associated with ACE; 2) ACE is
not the key factor that influences the concentration of T.
However, in the PCOS patients the total T concentrations
between the I/D and I/I genotypes were different, which
cannot be explained if ACE is not associated with the con-
centration of T. The most probable reason may be that the
ACE I/D polymorphisms is only one of the co-factors that
affects the etiopathogenisis of PCOS by interacting with
other factors. The I/D genotype is more susceptible to
hyperandrogenism.
Conclusion
The I/D polymorphisms in the ACE gene was not associ-
ated with the pathogenesis of PCOS. However, the poly-
morphisms were associated with the steroidogenesis in
the ovary. This suggests that although the I/D polymor-
phisms in the ACE gene were not the key etiological fac-
tor, it may be associated with the aggravated clinical
manifestations of PCOS.
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